.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Healthtrust
Novartis
Julphar
Cipla
Accenture
Deloitte
Argus Health
Chinese Patent Office

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,965,156

« Back to Dashboard

Which drugs does patent 5,965,156 protect, and when does it expire?


Patent 5,965,156 protects AMBISOME and is included in one NDA.

This patent has eighteen patent family members in thirteen countries.

Summary for Patent: 5,965,156

Title: Amphotericin B liposome preparation
Abstract:A novel composition and method for solubilizing amphiphilic drugs in a small amount of organic solvent for use in improved liposomes is disclosed. A phosphatidylglycerol is acidified in a small amount of organic solvent. The amphiphilic drug, such as Amphotericin B, suspended in organic solvent is then added to the acidified phosphatidylycerol and a soluble complex is formed between the phosphatidylglycerol and the amphiphilic drug. When the liposome composition incorporating the soluble complex is hydrated, the final pH of the hydrating aqueous buffer is carefully controlled. The Amphotericin B liposomes formed have markedly reduced toxicity.
Inventor(s): Proffitt; Richard T. (Arcadia, CA), Adler-Moore; Jill (Altadena, CA), Chiang; Su-Ming (Canoga Park, CA)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Application Number:08/469,251
Patent Claim Types:
see list of patent claims
Compound; Process; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AstellasAMBISOMEamphotericin bINJECTABLE, LIPOSOMAL;INJECTION050740-001Aug 11, 1997RXYesYes► Subscribe► Subscribe► SubscribeYFOR THE TREATMENT OF FUNGAL INFECTIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,965,156

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,770,290 Amphotericin B liposome preparation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,965,156

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany3864495► Subscribe
Denmark629388► Subscribe
Greece3003050► Subscribe
Spain2029330► Subscribe
European Patent Office0317120► Subscribe
Denmark175052► Subscribe
Canada1339008► Subscribe
Australia2416188► Subscribe
Australia598958► Subscribe
Austria66598► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Farmers Insurance
Dow
Johnson and Johnson
Fuji
UBS
Teva
Harvard Business School
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot